Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT06267846

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Conditions: Major Depressive Disorder

Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 73
Sponsor: Neurocrine Biosciences

Location: Neurocrine Clinical Site Little Rock Arkansas

Summary

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).

Eligibility Criteria

Key Inclusion Criteria: Participants must meet all of the following inclusion criteria: * Primary diagnosis of recurrent MDD or persistent MDD. * Participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior to screening and must be willing and able to continue with current antidepressant medication(s). * Participants must be willing and able to comply with all study procedures and restrictions. Key Exclusion Criteria: Participants will be excluded from the study if they meet any of the following criteria: * Participant is pregnant or breastfeeding or plan to become pregnant during the study. * Participant has an unstable medical condition or unstable chronic disease. * Participant has a history of neurological abnormalities. * Participant has a current or prior psychiatric disorder diagnosis that was the primary focus of treatment other than MDD. * Participant's depressive symptoms have previously demonstrated nonresponse to an adequate course of treatment with electroconvulsive therapy. * Participant has an alcohol or substance use disorder. Note: Other inclusion/exclusion criteria may apply

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06267846). StuddyBuddy aggregates publicly available trial information.